A few weeks after my late husband, Jeff, was diagnosed with ALS in 2018, we were sitting in our primary care doctor’s office to talk. We’d just received a second opinion confirming the diagnosis, and we were reeling. I remember how brutal the appointment felt for all three of us.
Recognizing the signs of angels who walk among us
Treatment with Radicava ORS (edaravone) significantly slowed declines in physical function and improved survival outcomes for people with amyotrophic lateral sclerosis (ALS) compared with historical controls from the PRO-ACT database who’d received a placebo in previous clinical trials. The findings were presented by Mitsubishi Tanabe Pharma…
It’s hard for me to get away from home because I’m the primary caregiver for my husband, Todd, who has ALS. But I try to take daily walks in the fields and woods around our house, because nature feeds my soul. Last weekend, I managed to go to the…
Neither memantine nor trazodone, two medications approved to treat other conditions, was able to slow disease progression in people with amyotrophic lateral sclerosis (ALS) who took part in a platform clinical trial, a study concluded. Based on the lack of benefits in the trial’s interim analysis, the two treatment…
Neuvivo’s investigational therapy NP001 (sodium chlorite), designed to dampen inflammation and restore immune system balance, extended survival in people with amyotrophic lateral sclerosis (ALS), according to an combined analysis of data, spanning up to 11 years, on patients who took part in either of two Phase 2…
One day, about four years after my diagnosis of ALS, I began having trouble pronouncing words. My tongue felt thick and couldn’t form words at the speed I was thinking them. My speech came out garbled and my brain hurt from trying to overcome the disconnect. At the time,…
An advisory committee from the European Medicines Agency (EMA) has upheld its opinion against granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for amyotrophic lateral sclerosis (ALS) in the European Union. The decision was taken in a meeting by the Committee for Medicinal…
The first patient has been dosed in a Phase 1/2 clinical trial of AMT-162, the one-time gene therapy in development by uniQure for treating amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene, when the condition is thus known as SOD1-ALS. The open-label EPISOD1 clinical…
It was six years ago last week that my late husband, Jeff, and I sat in a neurologist’s office in Maryland as the doctor said, “I believe that this is ALS.” Moments before, I’d been watching the doctor administer a second electromyography (EMG) on Jeff, who found the procedure…
An ultra-high dose of mecobalamin, a naturally occurring form of vitamin B12, has been approved in Japan under the brand name Rozebalamin to treat amyotrophic lateral sclerosis (ALS). The therapy, which will be manufactured and marketed by Eisai, is intended to slow functional decline in people with the…
Recent Posts
- After 15 years as an ALS caregiver, I’m still learning from others
- Early PrimeC use slows ALS progression, reduces complication risk
- Learning ALS self-advocacy involves being a little pushy
- Brain implant decodes finger moves so paralyzed patients can type
- Grant funds new ALS treatment approach targeting TDP-43 pathway